Belief BioMed Teams Up with AskBio for Gene Therapy Innovations
Belief BioMed Inc. (BBM), a trailblazing biotech firm recognized for its cutting-edge approaches to gene therapy, has announced an important collaboration with Asklepios BioPharmaceutical, Inc. (AskBio). This partnership is centered on harnessing the potential of new gene therapies, particularly aimed at conditions with significant unmet medical needs. They plan to utilize a liver-targeted strategy to develop effective treatments.
Strengthening the Future through Collaboration
The agreement between Belief BioMed and AskBio goes beyond a mere alliance; it symbolizes a fusion of expertise and resources in the realm of gene therapy technology. The co-founders of both companies share a deep commitment to advancing medical solutions, driving them to investigate innovative therapies tailored for patients requiring assistance. By combining their strengths, both organizations are set to speed up the discovery and implementation of transformative treatments.
Valuable Insights from Industry Leaders
Dr. Xiao Xiao, Co-founder and Chief Science Officer of Belief BioMed, highlighted the importance of this partnership by stating, "At Belief BioMed, we've made considerable progress since our inception, especially in gene therapy research and development. Our proprietary rAAV vector system has gained wide recognition in the industry. This collaboration with AskBio aligns seamlessly with our strategic objectives, significantly augmenting our ability to provide novel treatments to patients around the world."
AskBio's Commitment to Revolutionary Therapies
Based in North Carolina, AskBio is focused on developing life-saving medicines. The company has an extensive portfolio addressing various medical issues, including neuromuscular and cardiovascular diseases. They have successfully created numerous proprietary capsids and promoters, with some currently in clinical trials. Gustavo Pesquin, Chief Executive Officer of AskBio, acknowledged the remarkable contributions made by Dr. Xiao Xiao, stating that this collaboration embodies their approach to forming partnerships aimed at achieving therapeutic advancements for conditions that are not yet adequately addressed.
Tackling Unmet Medical Needs
As Belief BioMed works toward its mission, the company is dedicated to addressing a wide range of chronic diseases. With a robust pipeline that includes conditions such as hemophilia, Duchenne Muscular Dystrophy (DMD), Parkinson's disease, and osteoarthritis, their collaboration with AskBio stands ready to leverage advanced research and technology. Dr. Jane Zheng, Co-founder and Chief Executive Officer of Belief BioMed, underscored the commitment of their workforce and external collaborators to enhancing the company’s high-quality development while outlining the goals of the partnership. She expressed hope for expanding the scope of unmet medical needs that this collaboration can address.
A Bright Future for Gene Therapy
This partnership is more than about current initiatives; it builds a solid groundwork for the future of both companies in the gene therapy landscape. Through shared expertise and technology, they seek to strengthen their core competencies in developing innovative gene therapies. Belief BioMed is eager to enhance its global presence and integrate advancements in therapy development to cater to diverse patient populations.
About Belief BioMed
Belief BioMed Inc. (BBM) is devoted to transforming gene therapy by combining research, manufacturing, and clinical applications. The organization is committed to creating safe and effective gene therapies designed for various severe genetic and chronic disorders. By utilizing advanced viral vector technology, BBM has developed a suite of proprietary vector technologies and boasts a strong pipeline addressing numerous unmet clinical needs. As the company continues to evolve its capabilities, it is also heavily invested in producing critical gene therapy drugs, some of which are already undergoing clinical review.
Frequently Asked Questions
What is the focus of the collaboration between Belief BioMed and AskBio?
The collaboration focuses on developing new gene therapies, particularly for diseases with high unmet medical need, using a liver-targeted approach.
Who are the key leaders involved in this collaboration?
Key leaders include Dr. Xiao Xiao, Co-founder and Chief Scientific Officer of Belief BioMed, and Gustavo Pesquin, Chief Executive Officer of AskBio.
What therapeutic areas does Belief BioMed target?
Belief BioMed targets various areas including hemophilia, Duchenne Muscular Dystrophy, Parkinson's disease, and osteoarthritis.
How does this partnership benefit patients?
This partnership aims to accelerate the development of innovative treatments, providing patients with effective options for previously untreatable conditions.
What technologies are being utilized in this collaboration?
The companies will leverage gene therapy technology and a proprietary recombinant adeno-associated virus (rAAV) vector system among other proprietary methodologies.
